by ODWAdmin | May 22, 2026 | Uncategorized
In the fight against cancer, single-agent treatments often hit a wall as tumors adapt and develop resistance. This is especially true for aggressive cancers like non-small-cell lung cancer (NSCLC) with KRAS and LKB1 mutations, a hard-to-treat subtype. These challenges...
by ODWAdmin | May 22, 2026
Metabolomics for Mechanism of Action in Synergistic Cancer Treatments Next-Generation Metabolomics can provide robust, biologically meaningful data for drug combination analysis. Learn more about treatment-induced metabolic reprogramming and targeted combination...
by Jason Heaviland | Apr 28, 2026 | Uncategorized
What if untargeted metabolomics delivered on its promise? For years, untargeted metabolomics has been one of the most compelling approaches in biology: measure broadly, capture molecular diversity and improve biological interpretation and understanding. In practice,...
by Jason Heaviland | Apr 10, 2026 | Uncategorized
Terms like “comprehensive coverage” and “untargeted detection” are widely used in metabolomics, but they are rarely evaluated in controlled comparisons. Panome Bio conducted a head-to-head study against a widely used legacy platform using identical samples,...
by Jason Heaviland | Mar 31, 2026
Metabolomics Comparison: A Head-to-Head Study Panome Bio conducted a controlled head-to-head metabolomics study using identical samples analyzed by a legacy library-based platform and Next-Generation Metabolomics®️. The results show a nearly 4× increase in detected...
